Drug Trial Radar · NCT00210938
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Last checked: Nov 20, 2026Latest source record: Jun 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
478
Actual
Start
Mar 2004
Primary completion
Not stated
Study completion Jan 2006
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Peninsula Pharmaceuticals, Inc.
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.
Conditions
- Bacterial Infections and Mycoses
- Appendicitis
- Cholecystitis
- Pancreatitis
- Peritonitis
Interventions
DoripenemDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response rate measured at late follow-up visit.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.